reason report
solid qtr dividend defend grow estim go
pt
bottom line solid quarter continu
solid top-lin growth benefit earli growth new
immunolog brand continu solid perform oncolog
brand stabil previous slide sale humira
ex us market face biosimilar competit manag
comment decis increas dividend
reinforc confid compani maintain grow
dividend current level least anoth year
pend launch perform sever key medicin
potenti much longer earli perform key immunolog
product skyrizi rinvoq encourag particularli
humira also still grow domest overal compani deliv
top-lin ep beat versu consensu rais revenu
guidanc top end prior rang maintain
ep guidanc manag suggest confid
close allergan mp acquisit
outlin host import new indic approv treatment
recommend deadlin exist medicin howev none
commentari offer much way new nme opportun
focu compani respons question
allergan continu expect rapid extens job program
cut allergan merger still anticip return
deal-hunt sometim mid-to-l transact
put bed implement base updat model
expand peer compani multipl sinc earli octob
increas revenu ep estim increas price
target maintain outperform rate abbvi
dividend increas provid reassur confid futur
cash flow pro forma abbvie-allergan model suggest combin
compani free cash flow like exceed
beyond view compani capit deploy strategi like
continu focu capit return debt repay next
month pivot includ pipelin replenish
invest least assum take skeptic view
allergan clinic develop program
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
increas revenu forecast base stronger skyrizi uptak
slower humira eros price target increas reiter
op base latest sale trend manag commentari
disclosur increas revenu forecast
later year increas revenu forecast
recent consensu consensu
oper margin forecast less unchang
result pro forma ep estim increas
year larg line recent consensu ep
base chang estim revenu cash
flow ep chang peer compani multipl estim
denomin vs increas price target
reiter outperform rate expect continu
trade posit strength exist immunolog oncolog
asset expand indic opportun view
re-pric compani stock least top rang
larg biotech compani rang peer intern
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici plan acquisit allergan earli
allergan bring new revenu market categori outsid
current product portfolio allergan esthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan esthet busi cash flow without disrupt effect
busi unit innov cultur commerci effect ad allergan dilut
abbvi exposur humira posit offer compani
signific opportun oper effici synergi alreadi
disclos face mani challeng humira franchis rebat reform patent
challeng biosimilar pathway chang patent reform product cash flow
seem rel secur beyond two cornerston hematolog busi
grow strongli sever year least emerg combin neurosci portfolio
gener signific revenu posit cash flow earli import
pipelin program combin compani come skyrizi venclexta imbruvica
new indic signific increment opportun probabl allergan
neurolog migrain psychiatri schizophrenia program boost back
indic compani long sinc abandon see combin compani
deliv mid-singl digit revenu growth high singl digit ep growth
revenu beat consensu estim driven strong new brand
uptak perform hematolog oncolog portfolio
report sale y/i q/q beat consensu estim
driven strong skyrizi uptak good perform hematolog oncolog
skyrizi perform continu bullish trend sale increas significantli
beat consensu estim respect beat driven fast
adopt new switch patient manag indic physician
prescrib skyrizi patient treat drug sinc launch
compani confid skyrizi long -term growth commerci access
rinvoq also exceed expect first quarter partial quarter sale beat
consensu estim comment
commerci access ramp strongli expect access reach earli januari
expect paid prescript volum increas significantli next sever month accord
rinvoq current captur in-play ra patient vs skyrizi
imbruvica venclexta continu contribut strong top-lin growth global imbruvica
revenu grew y/i sequenti higher consensu
estim driven continu uptak first-lin chronic lymphocyt leukemia cll
estim
orilissa ramp still slower expect report sale miss consensu
estim hcv under-perform report sale
consensu lower estim weak perform led slightli
downward guidanc revis
non-gaap ep consensu estim
total non-gaap expens higher consensu flat vs us abbvi
report gross margin slightli lower consensu estim
manag indic lower gross profit margin due higher sale collabor
product abbvi non-gaap expens consensu
estim ga expens consensu
estim report higher oper margin compar consensu
estim due higher expens share collabor product tax rate
slightli lower consensu estim
abbvi slightli increas revenu narrow non-gaap ep guidanc
revenu guidanc increas yoy growth increas
oper fx impact non-gaap ep guidanc slightli increas
skyrizi guidanc increas manag also
increas venclexta guidanc imbruvica guidanc
pipelin updat mostli came label expans studi submiss
plan initi phase studi rinvoq treatment axial spa come
month compani indic psoriat arthriti axial spa key focu
abbvi immunolog portfolio compani also expect report rinvoq first registr
atop dermat data first half regard skyrizi registr studi
crohn diseas cd ulcer coliti uc progress track phase data
uc expect phase data cd besid immunolog expect
report phase data imbruvica venclexta combin treatment mantl cell
lymphoma mcl next year lastli compani expect present data phase studi
frontlin cll addit phase data next month combin
could major new treatment option patient signific increment revenu
opportun despit label expans opportun pipelin updat
conspicu lack import new molecular entiti nme reach proof concept
poc valid endpoint situat reinforc view allergan
acquisit bed still need net acquir innov product
increas revenu forecast base stronger skyrizi uptak slower
humira eros price target increas reiter op
base latest sale trend manag commentari disclosur increas
revenu forecast later year increas revenu
forecast recent consensu consensu
oper margin forecast less unchang result pro forma ep
estim increas year larg line recent consensu
ep base chang estim revenu cash flow ep
chang peer compani multipl estim denomin vs increas
price target reiter outperform rate expect continu trade
posit strength exist immunolog oncolog asset expand
indic opportun view re-pric compani stock least top
rang larg biotech compani rang peer intern pharmaceut
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani
midterm growth tail risk celg averag
consensu ep multipl appli current ep estim give
valu use revenu multipl similar compani
consensu sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
phase trial primari complet
fda action nda launch expect
phase data releas
open label studi sclc high
primari complet
primari complet
hmb uterin fibroid
nda file
confirm close
fda action nda launch expect
fda action bla launch expect
phase trial progress form ms
open label studi assess safety/toler
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
rhhbi sni celg appli expect revenu
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
non-gaap cost good sold
interest expens
abbvi guidanc
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
